CNS Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for CNS Pharmaceuticals (CNSP).

Price Target Range — 2 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$20Upside to Avg. PT+300.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 12, 2025	Maxim Group	Jason McCarthy	Upgrade	Hold→Buy	$20
Mar 25, 2025	Maxim Group	Jason McCarthy	Downgrade	Buy→Hold	—
Sep 10, 2024	Maxim Group	Jason McCarthy	Upgrade	Hold→Buy	$300

Analyst Ratings News

PRO
Maxim Group Upgrades CNS Pharma to Buy, Announces $20 Price Target

Maxim Group analyst Jason McCarthy upgrades CNS Pharma (NASDAQ:CNSP) from Hold to Buy and announces $20 price target.

Benzinga Newsdesk

PRO
Maxim Group Downgrades CNS Pharma to Hold

Maxim Group analyst Jason McCarthy downgrades CNS Pharma (NASDAQ:CNSP) from Buy to Hold.

Benzinga Newsdesk

PRO
Maxim Group Upgrades CNS Pharma to Buy, Announces $0.5 Price Target

Maxim Group analyst Jason McCarthy upgrades CNS Pharma (NASDAQ:CNSP) from Hold to Buy and announces $0.5 price target.

Benzinga Newsdesk

PRO
Brookline Capital Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $10

Brookline Capital analyst Raja Kumaraguru initiates coverage on CNS Pharmaceuticals (NASDAQ:CNSP) with a Buy rating and announces Price Target of $10.

Benzinga Newsdesk

Benzinga's Top Upgrades, Downgrades For August 24, 2020

Upgrades

Benzinga Insights

PRO
Ladenburg Thalmann Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $11

Ladenburg Thalmann analyst Robert LeBoyer initiates coverage on CNS Pharmaceuticals (NASDAQ:CNSP) with a Buy rating and announces Price Target of $11.

Benzinga Newsdesk

CNS Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

CNS Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Maxim Group Upgrades CNS Pharma to Buy, Announces $20 Price Target

PRO
Maxim Group Downgrades CNS Pharma to Hold

PRO
Maxim Group Upgrades CNS Pharma to Buy, Announces $0.5 Price Target

PRO
Brookline Capital Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $10

Benzinga's Top Upgrades, Downgrades For August 24, 2020

PRO
Ladenburg Thalmann Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $11

People Also Watch

People Also Watch

CNS Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

CNS Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMaxim Group Upgrades CNS Pharma to Buy, Announces $20 Price Target

PROMaxim Group Downgrades CNS Pharma to Hold

PROMaxim Group Upgrades CNS Pharma to Buy, Announces $0.5 Price Target

PROBrookline Capital Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $10

Benzinga's Top Upgrades, Downgrades For August 24, 2020

PROLadenburg Thalmann Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $11

People Also Watch

People Also Watch

PRO
Maxim Group Upgrades CNS Pharma to Buy, Announces $20 Price Target

PRO
Maxim Group Downgrades CNS Pharma to Hold

PRO
Maxim Group Upgrades CNS Pharma to Buy, Announces $0.5 Price Target

PRO
Brookline Capital Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $10

PRO
Ladenburg Thalmann Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $11